Cevian Capital Lifts Stake in Smith & Nephew to Over 13%

Smith & Nephew is facing increased activist pressure after Cevian Capital disclosed a voting stake of 13.206621% in the FTSE 100 medical technology company, according to a TR-1 regulatory filing.

Cevian Capital is one of Europe's most active activist investors, with a track record of taking significant stakes in underperforming listed companies and engaging with management to drive improvements in operating performance, capital allocation, or strategic focus. A 13% voting position in Smith & Nephew is a substantial activist stake, well above the thresholds typically required to exert meaningful influence at shareholder meetings.

Smith & Nephew has been under operational pressure in recent periods, with analysts noting that its 2026 growth targets appear challenging given softer demand in the US orthopaedics market -- one of the company's core segments covering hip and knee replacements. The company has been running a share buyback programme alongside efforts to improve margins and stabilise revenue growth.

Cevian's stake increase signals a willingness to deepen engagement with the company's strategy. Activist campaigns at this level of ownership typically develop over quarters to years, with potential outcomes ranging from management changes and cost programmes to portfolio restructuring or a transaction. Smith & Nephew's recent underperformance relative to medtech peers has made it a candidate for activist interest for some time.

The TR-1 filing represents a formal disclosure trigger, indicating the stake crossed a regulatory reporting threshold as Cevian continued to accumulate shares.